Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 1/20 | 0.31 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.31 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14322797 | 0.93 | EGFR (0.32) | EGFR | |
| SCHEMBL14322436 | 0.82 | AURKA (0.32) | AURKAAURKB | |
| Hydrochloric Acid SCHEMBL5752769 | 0.68 | EGFR (0.39) | AURKBEGFR | |
| SCHEMBL14323906 | 0.67 | CLK1 (0.52) | — | |
| SCHEMBL14323013 | 0.67 | CLK1 (0.53) | — | |
| SCHEMBL14323532 | 0.67 | ABCG2 (0.49) | EGFR | |
| SCHEMBL14322821 | 0.66 | ACP1 (0.46) | EGFR | |
| SCHEMBL14322507 | 0.66 | MAPK1 (0.53) | — | |
| SCHEMBL14323804 | 0.65 | IGF1R (0.50) | AURKAAURKB | |
| SCHEMBL1391792 | 0.65 | NFKB1 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9499535-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2016-11-22 | — | — | US | disclosed |
| EP-2699572-B1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2016-08-10 | — | — | EP | disclosed |
| US-20120329785-A1 | Novel kinase inhibitors | ORIGENIS GMBH (DE) | 2012-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120329785-A1 | Novel kinase inhibitors | LRRK2, MYLK2, MYLK3 | AURKA 841/4885AURKB 381/4885EGFR 1207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.